7.16BMarket Cap-10278P/E (TTM)
4.300High4.030Low5.44MVolume4.280Open4.310Pre Close22.32MTurnover0.36%Turnover RatioLossP/E (Static)1.76BShares9.73052wk High0.91P/B6.08BFloat Cap4.03052wk Low--Dividend TTM1.50BShs Float32.050Historical High--Dividend LFY6.27%Amplitude4.030Historical Low4.100Avg Price1000Lot Size--Div YieldTTM--Div Yield LFY
INNOCARE Stock Forum
ColumnsStudy Results of Orelabrutinib in Patients with ITP Published by the American Journal of Hematology
ColumnsInnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib
ColumnsInnoCare Releases 2023 Results and Business Highlights
Financial Highlights
• Revenue increased by 18.1% to RMB738.5 million in 2023, including RMB670.7 million from orelabrutinib, an increase of 18.5%, mainly due to the continuous and rapid ramp-up of orelabrutinib sales.
• Gross ...
ColumnsInnoCare to Host 2023 Earnings Call on March 28, 2024
ColumnsInnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma in China
ColumnsLatest data of InnoCare's ICP-332 for the Treatment of Atopic Dermatitis Presented at LBA Session of 2024 AAD
ColumnsInnoCare Announces First Pediatric Patient Dosed in Clinical Trial of pan-TRK Inhibitor Zurletrectinib in China
ColumnsInnoCare Announces First Prescription of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma Under Greater Bay Area’s Early Access Program
ColumnsInnoCare Announces Clearance of Clinical Trial of BCL2 Inhibitor ICP-248 by U.S. FDA
This is a Phase I study to evaluate the...
No comment yet